Capricor Therapeutics, Inc., (NASDAQ: CAPR), a biotechnology company focused on the discovery, development, and commercialization of first-in-class therapeutics, announced, on Friday, November 6, 2015, that results will be presented from its ongoing Phase I DYNAMIC (Dilated Cardiomyopathy Intervention with Allogeneic Myocardially Regenerative Cells) clinical trial evaluating CAP-1002 in patients with advanced heart failure. The data will be presented in a poster to be delivered at the 2015 American Heart Association (AHA) Scientific Sessions taking place November 7-11, 2015 in Orlando, Florida. The poster is titled “Dilated Cardiomyopathy Intervention with Allogeneic Myocardially Regenerative Cells (DYNAMIC): Six Month Safety and Exploratory Efficacy Results,” and it will be presented on Monday, November 9, 2015, 5:30 - 6:45 pm ET in Poster Hall, A2, BS, in the “APS.06.02. Stem/Progenitor Cells II” session (Poster Number: M 104). CAP-1002 is Capricor's lead investigational allogeneic, cardiosphere-derived-cell (CDC) therapy. The Phase I DYNAMIC trial is evaluating CDCs (CAP-1002) (http://capricor.com/product-pipeline/cap-1002/) in patients with advanced heart failure. The trial enrolled 14 patients with either ischemic or non-ischemic dilated cardiomyopathy with left ventricular ejection fraction (LVEF) of 35% or below and New York Heart Association (NYHA) Class III or Ambulatory Class IV heart failure. Suitable patients underwent sequential intracoronary infusion of CAP-1002 in up to three coronary territories. The primary safety endpoints were assessed at the 1-month visit. Other safety and exploratory efficacy endpoints, including ejection fraction, ventricular volumes, and a six-minute walk test were evaluated at 6 months and will be evaluated at a 12-month follow-up.Login Or Register To Read Full Story